Aspirin-resistant platelet aggregation in a cohort of patients with coronary heart disease
Authors:
- Burak PamukcuBPBurak Pamukcu
- Huseyin OflazHOHuseyin Oflaz
- Imran OnurIOImran Onur
- Aytac OnculAOAytac Oncul
- Berrin UmmanBUBerrin Umman
- Nevres KoylanNKNevres Koylan
- Zehra BugraZBZehra Bugra
- Mehmet MericMMMehmet Meric
- Yilmaz NisanciYNYilmaz Nisanci
- 1 July 2007
- journal article
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 18 (5) , 461-465
Abstract
Aspirin resistance could be defined as thrombotic and embolic cardiovascular events despite regular aspirin therapy. The study aimed to determine the profile and prevalence of aspirin resistance in coronary artery disease patients. We evaluated the prevalence of aspirin resistance in a cohort of 505 patients with the diagnosis of coronary artery disease taking 80–300 mg regular aspirin daily. Platelet functions were analyzed by the Platelet Function Analyzer (PFA)-100 with collagen and epinephrine cartridges and collagen and ADP cartridges. A closure time of 186 s or less with the collagen and epinephrine cartridge was defined as aspirin resistance. Of the patients, 118 (23.4%) were aspirin resistant by the PFA-100. Aspirin-resistant patients were more likely to be older than aspirin-sensitive patients (P = 0.024). No statistically significant differences between the aspirin-resistant and aspirin-sensitive individuals were present in gender, major risk factors of coronary artery disease, number and localization of involved coronary vessels, serum lipid levels, and blood counts. According to the high prevalence of coronary heart disease, many people are affected by aspirin resistance, which may play a role in adverse cardiovascular events. Monitoring of platelet function in patients with coronary heart disease may support the optimization of antiplatelet therapy with additional and/or alternative agents.Keywords
This publication has 16 references indexed in Scilit:
- The Role of Exercise on Platelet Aggregation in Patients with Stable Coronary Artery Disease: Exercise Induces Aspirin Resistant Platelet ActivationJournal of Thrombosis and Thrombolysis, 2005
- The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosisAmerican Heart Journal, 2005
- Resistance in vitro to low-dose aspirin is associated with platelet PlA1(GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T kozak (GP Ibα) polymorphismsJACC, 2003
- Overexpression of Functionally Coupled Cyclooxygenase-2 and Prostaglandin E Synthase in Symptomatic Atherosclerotic Plaques as a Basis of Prostaglandin E 2 -Dependent Plaque InstabilityCirculation, 2001
- Cyclooxygenase-1 and -2–Dependent Prostacyclin Formation in Patients With AtherosclerosisCirculation, 2000
- Increased Platelet Sensitivity to Collagen in Individuals Resistant to Low-Dose AspirinStroke, 2000
- Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin.Circulation, 1994
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 1994
- The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: Clinical evidence from the physicians' health studyAmerican Heart Journal, 1991
- Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment.Journal of Clinical Investigation, 1991